meta_analysis
    2017

    Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: An individual subject meta-analysis

    Cayzeele-Decherf A, Pelerin F, Leuillet S, Douillard B, Housez B, Cazaubiel M, Jacobson GK, Justen P, Desreumaux P

    Published in World Journal of Gastroenterology

    Key Findings

    Pooled individual data from 579 IBS subjects showed improvement in abdominal pain/discomfort and bloating scores with S. cerevisiae CNCM I-3856 versus placebo, strongest in IBS-C.

    Conclusions

    A specific yeast probiotic reduces bloating in a subset of IBS patients.

    Limitations

    Both pooled trials industry-sponsored; single strain; modest effect sizes.

    Supplements Studied

    Probiotics
    Probiotic

    An individual patient data meta-analysis was performed on two randomized clinical trials studying the effect of S. cerevisiae CNCM I-3856 supplementation on gastrointestinal (GI) symptoms in IBS subjects.

    Outcomes Measured

    Outcomes were the daily Likert scale scores of abdominal pain/discomfort and bloating.

    Study Details

    Year:2017
    Sample Size:579
    Duration:8 weeks
    Quality Score:6/10

    This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.